Genital Herpes Market
Genital Herpes Market Infographics

Genital Herpes

Genital herpes is a chronic Sexually Transmitted Infection (STI) characterized by blisters and open sores (lesions) in the genital area. It is caused by the Herpes Simplex Virus (HSV), which is of two types, HSV-1

and HSV-2.

The virus becomes active for some time and then returns to a dormant state; when active, they travel to the surface of the infected area (skin or mucous membrane) and makes copies of itself. This is called “shedding” since, in this stage, the viruses can rub off and transfer to another person.


Genital Herpes Epidemiology Segmentation in the 7MM


  • Prevalent HSV-infected cases
  • Symptomatic Genital Herpes cases
  • Genital Herpes cases by gender
  • Diagnosed Genital Herpes cases
  • Total recurrent cases of Genital Herpes
  • Treated patient pool of Genital Herpes


Genital Herpes Epidemiological Insights Observed in the 7MM (2021)

The total number of incident cases of Genital Herpes observed in the 7MM was observed to be ~2 million in the year 2021


Genital Herpes Market Insight


  • The market size of Genital Herpes in the 7MM + China was found to be approximately USD 1,125 million in 2021
  • The market size of Genital Herpes in the United States was found to be approximately USD 1,125 million in 2021
  • The market size of Genital Herpes in the EU5 was found to be approximately USD 342 million in 2021
  • The market size of Genital Herpes in the Japan was found to be approximately USD 69 million in 2021
  • The market size of Genital Herpes in the China was found to be approximately USD 296 million in 2021


Genital Herpes Market Strengths

Genital herpes is a common sexually transmitted disease. With the increase in the population of various regions, there is also an increase in the rate of health issues worldwide. As the rate of diseases grows, the treatment markets are also expected to grow substantially.


Genital Herpes Market Opportunities

Various big Pharma key players are currently active in the development of a novel drug for the treatment of MG.


Genital Herpes Emerging Drugs and key Companies


  • AIC-316 (pritelivir): AiCuris
  • UB-621: United BioPharma
  • HDIT101: Heidelberg ImmunoTherapeutics
  • SIMPLIRIX (GSK208141): GlaxoSmithKline
  • GEN-003: Genocea Biosciences
  • HerpV (AG-707): Agenus
  • VCL-HB01: Fresh Tracks Therapeutics
  • SP-0148: Sanofi, and others